BETHESDA, Md., Sept.

VioQuest Pharmaceuticals (OTCBB: VOQP) announced today that the company's novel Akt inhibitor VQD-002 (triciribine phosphate monohydrate, or TCN-P) has been selected as one of the Top 10 most promising oncology projects in development available for strategic partnering by an independent committee assembled by Windhover Information, a leading provider of business information products and services to senior executives in the pharmaceutical, biotechnology, and medical device industries.

BOSTON, Nov. 2 /PRNewswire/ -- Surface Logix Inc. announced today that the Company's lead clinical candidate, SLx-2101, has been selected as one of the top ten most promising cardiovascular drugs in development, offering significant potential for strategic partnering.